Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas’ digital shift plans.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 January 2022, including: Johnson & Johnson considers bold M&A moves; a prominent new CEO for Galapagos NV; Biogen, Inc.’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas Pharma, Inc.’s digital shift plans.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pharma R&D Legend Stoffels To Take Helm At Galapagos" - Scrip, 27 Jan, 2022.)
(Also see "Biogen's Singhal On Stepping Into R&D Leadership Shoes Amid Aduhelm Controversy" - Scrip, 26 Jan, 2022.)
(Also see "Stock Watch: Biogen, Blood In The Water" - Scrip, 24 Jan, 2022.)
(Also see "Astellas Positions Patients At Center Of Digital Push" - Scrip, 26 Jan, 2022.)